Contact
searchSearch
HMP Global
Login

Oncology

Featured

News
Safusidenib Erbumine Shows Promise in Newly Diagnosed IDH1-Mutated Grade 2 Gliomas
12/05/2025
Stephanie Holland
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a...
12/05/2025
Oncology
News
Vorasidenib Added to Temozolomide Shows Favorable Safety in IDH1/2-Mutated Gliomas
12/05/2025
Stephanie Holland
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial...
12/05/2025
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed/Refractory Marginal Zone Lymphoma
12/04/2025
Emily Estrada
On December 4, 2025, the FDA has approved lisocabtagene maraleucel for adult patients with relapsed/refractory marginal zone lymphoma who have received at least 2 prior lines of systemic therapy.
On December 4, 2025, the FDA has approved lisocabtagene maraleucel for adult patients with relapsed/refractory marginal zone lymphoma who have received at least 2 prior lines of systemic therapy.
On December 4, 2025, the FDA has...
12/04/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
High-Sensitivity Calcitonin Testing Establishes New Cutoffs for Nodal Metastasis in Medullary Thyroid Cancer
12/04/2025
Stephanie Holland
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
News
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L LBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
FDA Approval
FDA Approves Pirtobrutinib for R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/03/2025
Stephanie Holland
Based on results from the BRUIN-CLL-321 study, the FDA granted traditional approval to pirtobrutinib for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a BTK inhibitor.
Based on results from the BRUIN-CLL-321 study, the FDA granted traditional approval to pirtobrutinib for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a BTK inhibitor.
Based on results from the...
12/03/2025
Oncology
Quiz
CAR T-Cell Therapies and Survival Outcomes Among Patients With R/R FL
12/03/2025
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to...
12/03/2025
Oncology

Videos

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Joshua Richter, MD
Conference Coverage
Addressing Disparities in CAR-T Access in Treating Multiple Myeloma
12/01/2025
Joshua Richter, MD
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares...
12/01/2025
Oncology
Mark Bustoros, MD
Conference Coverage
Utilizing Genomic Profiling to Refine Risk Stratification for Smoldering and Newly Diagnosed Multiple Myeloma
12/01/2025
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how...
12/01/2025
Oncology
Macarena De La Fuente, MD
Videos
Evaluation of Vorasidenib Plus Temozolomide in IDH1/2-Mutated Glioma
11/22/2025
Macarena De La Fuente, MD, discusses results from a phase 1b study that evaluated the safety and tolerability of vorasidenib plus temozolomide in patients with IDH1/2-mutated glioma.
Macarena De La Fuente, MD, discusses results from a phase 1b study that evaluated the safety and tolerability of vorasidenib plus temozolomide in patients with IDH1/2-mutated glioma.
Macarena De La Fuente, MD,...
11/22/2025
Oncology
Video Thumbnail
Videos
Emerging Data on Alpha-Emitter Therapies
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving...
11/18/2025
Oncology
Video Thumbnail
Videos
Mechanism of Action: Beta vs Alpha Emitters
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and...
11/18/2025
Oncology
Video Thumbnail
Videos
Practical Application and Patient Selection for PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor...
11/18/2025
Oncology

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
Safusidenib Erbumine Shows Promise in Newly Diagnosed IDH1-Mutated Grade 2 Gliomas
12/05/2025
Stephanie Holland
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a...
12/05/2025
Oncology
News
Vorasidenib Added to Temozolomide Shows Favorable Safety in IDH1/2-Mutated Gliomas
12/05/2025
Stephanie Holland
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial...
12/05/2025
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed/Refractory Marginal Zone Lymphoma
12/04/2025
Emily Estrada
On December 4, 2025, the FDA has approved lisocabtagene maraleucel for adult patients with relapsed/refractory marginal zone lymphoma who have received at least 2 prior lines of systemic therapy.
On December 4, 2025, the FDA has approved lisocabtagene maraleucel for adult patients with relapsed/refractory marginal zone lymphoma who have received at least 2 prior lines of systemic therapy.
On December 4, 2025, the FDA has...
12/04/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
High-Sensitivity Calcitonin Testing Establishes New Cutoffs for Nodal Metastasis in Medullary Thyroid Cancer
12/04/2025
Stephanie Holland
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
News
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L LBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
FDA Approval
FDA Approves Pirtobrutinib for R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/03/2025
Stephanie Holland
Based on results from the BRUIN-CLL-321 study, the FDA granted traditional approval to pirtobrutinib for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a BTK inhibitor.
Based on results from the BRUIN-CLL-321 study, the FDA granted traditional approval to pirtobrutinib for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a BTK inhibitor.
Based on results from the...
12/03/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use